Nov. 6 at 3:10 PM
$CDNA
CareDx, a player in the transplantation diagnostics market, has shown resilience and innovation with its latest financials revealing a significant turnaround. From a net loss of
$10.64 million to a net income of
$1.68 million this quarter, alongside revenue jumping from
$82.88 million to
$100.06 million year-over-year, the company's recovery is notable. This performance aligns with their raised full-year revenue forecast now set between
$372 million and
$376 million, reflecting confidence in continued growth driven by advancements like the SHORE study for heart transplant surveillance and new leadership under Dr. Jeffrey Teuteberg as CMO—further cementing its foothold in high-stakes medical technology sectors.
